Crinetics Pharmaceuticals Inc
NASDAQ:CRNX

Watchlist Manager
Crinetics Pharmaceuticals Inc Logo
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Watchlist
Price: 30.47 USD -1.55% Market Closed
Market Cap: 2.9B USD

Operating Margin
Crinetics Pharmaceuticals Inc

-49 569.7%
Current
-13 433%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-49 569.7%
=
Operating Profit
-376.7m
/
Revenue
760k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
2.8B USD
-49 570%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
330.5B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.4B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
137.2B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
127.5B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.7B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Crinetics Pharmaceuticals Inc
Glance View

Market Cap
2.8B USD
Industry
Biotechnology

In the intricate world of biotechnology, Crinetics Pharmaceuticals Inc. emerges as a keen innovator dedicated to the pursuit of novel therapeutics for endocrine disorders. Established with a mission to harness scientific curiosity into tangible medical solutions, Crinetics focuses on developing oral, small-molecule drugs designed to offer superior treatment alternatives for conditions that involve hormonal imbalances. The company's journey began with a deep dive into endocrine biology, aiming to address complex diseases that are underserved by current therapies. By capitalizing on its proprietary expertise in drug discovery and translational research, Crinetics has carved out a niche in developing non-invasive treatments that uniquely target peptide hormones and their receptors. Crinetics' business model hinges on a meticulous research and development pipeline, pushing its innovation from the laboratory into the clinical trial stage. With a keen eye on niche markets, the company leverages its scientific advances to design drugs that can be easily administered and are cost-effective compared to traditional treatments. The fundamental revenue drivers for Crinetics include partnerships and collaborations with larger pharmaceutical firms, which help it scale and market its pioneering therapies. As its drug candidates advance through the phases of development, the promise of royalty and milestone payments from these collaborations provides a crucial financial lifeline, driving the company closer to its ultimate goal of delivering life-changing therapies to patients worldwide.

CRNX Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-49 569.7%
=
Operating Profit
-376.7m
/
Revenue
760k
What is the Operating Margin of Crinetics Pharmaceuticals Inc?

Based on Crinetics Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -49 569.7%.

Back to Top